Year: 2022

Achiko AG Announces Annual Results for the Year Ended December 31, 2021

Achiko AG Announces Annual Results for the Year Ended December 31, 2021

ZURICH, Switzerland, June 26, 2022 (GLOBE NEWSWIRE) — Achiko AG (OTCQB: ACHKF; SIX: ACHI; ISIN CH0522213468) (“Achiko”, the “Company”) announces its financial results for the year ended December 31, 2021, and progress since then. For the year ended December 31, 2021, the Group recorded a net loss of USD $9,231,779 resulting in an increase of the Group’s accumulated losses to USD $34,568,395. The Company also notes that Achiko AG is currently managing creditors, and that while the assets of the Group at the reporting date was negative $4.584m, it also has over $2.4m in subordinated loans. As a result, the Company’s auditors have given an adverse opinion, noting the Company’s ability to remain a going concern depends on the successful approval of an increase in Authorised Capital at the upcoming General Meeting, and the support of...

Continue reading

Yaouré Mine Accident

Yaouré Mine Accident

PERTH, Western Australia, June 26, 2022 (GLOBE NEWSWIRE) — Perseus Mining Limited (ASX/TSX: PRU) regrets to advise that one of our colleagues, Mr Alohou Didier Leon Hamed, an employee of our mining contractor, EPSA Group, was fatally injured while working at our Yaouré Gold Mine in Côte d’Ivoire on Friday, June 24, 2022. We express our deepest sympathies to Mr Hamed’s family, and both Perseus and EPSA are providing support to help the family through this difficult time. Perseus is also offering support to our entire team at Yaouré as they come to terms with this tragic loss of a colleague. Perseus has commenced an investigation into the incident and are consulting with the relevant Ivorian Authorities. This announcement was approved for release by the Jeff Quartermaine, Managing Director and CEO. ASX/TSX CODE: PRU REGISTERED...

Continue reading

Prairie Provident Announces New Board Member

Prairie Provident Announces New Board Member

CALGARY, Alberta, June 26, 2022 (GLOBE NEWSWIRE) — Prairie Provident Resources Inc. (“Prairie Provident”, “PPR” or the “Company”) is pleased to announce the appointment of Matthew Shyba to its Board of Directors (the “Board”), effective July 1, 2022. Mr. Shyba owns 4,238,097 common shares of PPR, representing approximately 3.3% of the issued and outstanding common shares of PPR. He is a corporate lawyer and private investor with over 10 years of capital markets experience, with significant expertise in corporate finance, corporate governance and mergers & acquisitions. In addition, he is currently Chief Executive Officer of Shyba Capital Inc., a private investment company based in Calgary. Mr. Shyba previously practiced in the securities and capital markets group at Borden Ladner Gervais LLP and subsequently held senior legal...

Continue reading

Non-work related loss of life

Non-work related loss of life

NEW YORK, June 25, 2022 (GLOBE NEWSWIRE) — Mercer International Inc. (“Mercer” or the “Company”) (Nasdaq: MERC) is deeply saddened to announce that an employee has passed away at its Rosenthal mill in Germany on June 25, 2022. Mercer and local authorities conducted an investigation and so far determined that the tragic loss was not work related. Mercer’s emergency procedures were immediately activated, local authorities were notified and industrial safety and occupational health personnel were involved for support. “We are saddened about the loss of life of one of our employees and our thoughts are with the individual’s family and colleagues,” stated Christian Soergel, Managing Director of Mercer Rosenthal. “Given the nature of the incident, we will be respecting the privacy of our employee’s family and will continue providing...

Continue reading

Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program

Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program

– Results from ongoing trials of VIR-2218 and VIR-3434 presented at the International Liver Congress™ (ILC) 2022 demonstrate durable reductions in hepatitis B surface antigen with no safety signals – – Company expects to dose first patient in Part B of the Phase 2 MARCH trial by the end of June – SAN FRANCISCO, June 25, 2022 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from its robust hepatitis B virus (HBV) clinical trial program, including results from an ongoing Phase 2 clinical trial of VIR-2218, results from an ongoing Phase 1 clinical trial of VIR-3434 and preclinical data evaluating both investigational compounds as monotherapy and in combination. Data were presented in one oral and two poster presentations at the International Liver Congress™ (ILC) 2022, the Annual Meeting of the European...

Continue reading

Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™

Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™

PRESS RELEASE Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™ IMC-I109V, T cell receptor bispecific, targets an envelope antigen Single Ascending Dose portion of Phase 1 study to evaluate safety, antiviral activity, and pharmacokinetics In the initial cohort, HBsAg declines and ALT elevations indicated that a single, very low dose of IMC-I109V elicited on-target activity, consistent with mechanism of action and without any adverse events (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 25 June 2022) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed...

Continue reading

Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB-836 Clinical Update

Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB-836 Clinical Update

AB-729, our RNAi therapeutic, provided robust and comparable HBsAg declines in both HBeAg+ and HBeAg- patients 50% (16 out of 32) of patients maintained HBsAg levels below 100 IU/mL 24 weeks after their last AB-729 dose In the first five patients who discontinued both AB-729 and NA therapy after meeting stopping criteria, there has been no evidence of virologic or clinical relapse in 8-24 weeks of follow-up Preliminary data to date have shown that AB-729 remains generally safe and well-tolerated after completing dosing in 41 patients AB-729 continues to restore HBV-specific T-cells and decrease exhausted T-cells AB-836, our oral capsid inhibitor, dosed at 100mg or 200mg once daily for 28 days, achieved mean declines in HBV DNA of 3.04 and 3.55 log10, respectively, however safety findings warrant further evaluation in healthy volunteers...

Continue reading

Corporate Update: Smart Employee Benefits Inc. Announces Amendment to Credit Facility

Corporate Update: Smart Employee Benefits Inc. Announces Amendment to Credit Facility

MISSISSAUGA, Ontario, June 24, 2022 (GLOBE NEWSWIRE) — Smart Employee Benefits Inc. (“SEB” or the “Company”) (TSXV: SEB) (OTCQB: SEBFF) a leader in benefits processing solutions and services today announced that it has entered into a third amending agreement to its secured revolving credit facility agreement (the “Credit Agreement”) with its international asset-focused lender (the “Lender”) to, among other things, extend availability to $15,000,000 under the existing Credit Agreement. Co-operators Financial Services Limited (“Co-operators”), a strategic investor in SEB, previously provided a limited guarantee (the “Initial Guarantee”) of $5,000,000 in favour of the Lender, which Initial Guarantee permitted SEB to access $5,000,000 of unutilized commitment under the Credit Agreement. Subsequently, Co-operators provided an amended...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.